Lactobacillus crispatus and Reduced Cystitis Episode

Safety in these studies

Overall tolerabilityReported
Across pilot, phase II, and randomized trials, Lactobacillus vaginal therapy has demonstrated a generally favorable safety and tolerability profile, with preliminary evidence suggesting a potential to reduce recurrent cystitis episodes while restoring a Lactobacillus-dominant vaginal microbiota.
from: Unraveling the vaginal microbiota-based etiology of recurrent cystitis: the potential role

1 of 1 paper

Unraveling the vaginal microbiota-based etiology of recurrent cystitis: the potential role of Lactobacillus vaginal suppositories.

2026-05
Review
Therapeutic advances in urology 18
- Takanori Sekito
- Hidetada Hirakawa
- Takuya Sadahira

PubMed: 42137495
DOI: 10.1177/17562872261448600

2 Insights on

Reduced Cystitis Episode

Low evidence
Clinical

Lactobacillus vaginal therapy has demonstrated a generally favorable safety and tolerability profile, with preliminary evidence suggesting a potential to reduce recurrent cystitis episodes while restoring a Lactobacillus-dominant vaginal microbiota.

Effect: Beneficial
Effect size: Small
Significant: No